Jaguar Health (JAGX) Total Non-Current Liabilities (2014 - 2026)
Jaguar Health (JAGX) posted quarterly Total Non-Current Liabilities of $53.0 million for Q1 2026, up 375.84% year-over-year from $11.1 million in Q1 2025, and up 111.07% quarter-over-quarter from $25.1 million in Q4 2025.
Jaguar Health (JAGX) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Total Non-Current Liabilities for 13 consecutive years, with $53.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 375.84% year-over-year to $53.0 million; the TTM figure through Mar 2026 stood at $53.0 million (up 375.84% YoY), while the FY2025 annual figure was $25.1 million, up 176.24% from the prior year.
- Total Non-Current Liabilities improved to $53.0 million in Q1 2026 per JAGX's latest filing, from $25.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $53.0 million in Q1 2026 and bottomed at $9.1 million in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $22.3 million across 5 years, with a median of $14.7 million in 2025.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities tumbled 63.57% — and 2026, when it soared 375.84%.
- Jaguar Health's Total Non-Current Liabilities stood at $41.0 million in 2022, then sank by 63.57% to $14.9 million in 2023, then slumped by 39.09% to $9.1 million in 2024, then jumped by 176.24% to $25.1 million in 2025, then soared by 111.07% to $53.0 million in 2026.
- Business Quant data shows JAGX's Total Non-Current Liabilities at $53.0 million in Q1 2026, $25.1 million in Q4 2025, and $14.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | 26.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.00 Mn |
| Dec 31, 2025 | 25.11 Mn |
| Sep 30, 2025 | 14.69 Mn |
| Jun 30, 2025 | 12.58 Mn |
| Mar 31, 2025 | 11.14 Mn |
| Dec 31, 2024 | 9.09 Mn |
| Sep 30, 2024 | 10.09 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 14.92 Mn |
| Dec 31, 2022 | 40.97 Mn |
| Mar 31, 2022 | 44.80 Mn |
| Dec 31, 2021 | 41.41 Mn |
| Sep 30, 2021 | 37.70 Mn |
| Jun 30, 2021 | 37.75 Mn |
| Mar 31, 2021 | 36.81 Mn |
| Dec 31, 2020 | 25.64 Mn |
| Sep 30, 2020 | 28.30 Mn |
| Jun 30, 2020 | 21.07 Mn |
| Mar 31, 2020 | 15.42 Mn |
| Dec 31, 2019 | 14.34 Mn |